Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.172
-0.068 (-5.48%)
May 21, 2026, 12:53 PM CET
Diamyd Medical AB Market Cap
Diamyd Medical AB has a market cap or net worth of 192.18 million as of May 21, 2026. Its market cap has decreased by -79.95% in one year.
Market Cap
192.18M
Enterprise Value
1.45M
Revenue
362.00K
Ranking
n/a
PE Ratio
n/a
Stock Price
1.17
Market Cap Chart
Since May 20, 2013, Diamyd Medical AB's market cap has increased from 132.51M to 192.18M, an increase of 45.03%. That is a compound annual growth rate of 2.90%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 20, 2026 | 192.18M | -87.59% |
| Dec 30, 2025 | 1.55B | -9.52% |
| Dec 30, 2024 | 1.71B | 182.47% |
| Dec 29, 2023 | 605.80M | -41.10% |
| Dec 30, 2022 | 1.03B | -9.66% |
| Dec 30, 2021 | 1.14B | -46.65% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Isofol Medical AB | 229.15M |
| Xbrane Biopharma AB | 228.72M |
| Initiator Pharma | 210.15M |
| Xintela AB | 199.81M |
| Active Biotech AB | 173.45M |
| Nanologica AB | 161.10M |
| AlzeCure Pharma AB | 160.88M |
| Elicera Therapeutics AB | 145.61M |